Your session is about to expire
← Back to Search
Senolytic
Dasatinib + Quercetin for Obesity
Phase 2 & 3
Recruiting
Led By Nicolas Musi, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4 and week 15
Summary
This trial will involve taking samples of fat tissue from the abdomen of all participants to study their cells and molecules. The participants will also undergo tests to measure their insulin sensitivity, glucose tolerance, and function of
Who is the study for?
This trial is for lean individuals aged 18-30 or those over 65 with a healthy BMI, from any race and living in the community. They must be sedentary, nondiabetic, not pregnant or breastfeeding, and willing to use effective contraception. Participants should have normal blood sugar levels and ECG readings.
What is being tested?
The study tests how lifestyle changes compare to senolytics (Dasatinib plus Quercetin) versus placebo in older obese adults. It involves baseline biopsies of belly fat for cellular analysis and checks on insulin sensitivity, glucose tolerance, and β-cell function.
What are the potential side effects?
Possible side effects include reactions at the biopsy site like pain or bruising; Dasatinib may cause immune system issues or bleeding problems; Quercetin could lead to headaches or tingling sensations.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 4 and week 15
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 and week 15
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Glucose tolerance
Insulin sensitivity
Secondary study objectives
Senescence-associated secretory phenotype (SASP)
Trial Design
3Treatment groups
Experimental Treatment
Group I: Younger Lean GroupExperimental Treatment1 Intervention
Participants will be aged 18-30 years and have a BMI of 18.5 - 24.9 kg/m2
Group II: Older Obese GroupExperimental Treatment5 Interventions
Participants will be over 65 years of age with a BMI of 30-39.9 kg/m2.
Group III: Older Lean GroupExperimental Treatment1 Intervention
Participants will be over 65 years of age with a BMI of 18.5 to 24.9 kg/m2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
477 Previous Clinical Trials
92,810 Total Patients Enrolled
6 Trials studying Obesity
990 Patients Enrolled for Obesity
Cedars-Sinai Medical CenterLead Sponsor
513 Previous Clinical Trials
163,229 Total Patients Enrolled
7 Trials studying Obesity
965 Patients Enrolled for Obesity
National Institute on Aging (NIA)NIH
1,803 Previous Clinical Trials
28,194,351 Total Patients Enrolled
47 Trials studying Obesity
13,473 Patients Enrolled for Obesity
Nicolas Musi, MDPrincipal InvestigatorCedars-Sinai Medical Center
5 Previous Clinical Trials
86 Total Patients Enrolled
1 Trials studying Obesity
12 Patients Enrolled for Obesity